Enhanced tuberculosis case detection among substitution treatment patients: a randomized controlled trial by Rüütel, Kristi et al.
SHORT REPORT Open Access
Enhanced tuberculosis case detection among
substitution treatment patients: a randomized
controlled trial
Kristi Rüütel
1*, Helle-Mai Loit
2†, Tiiu Sepp
3†, Kai Kliiman
4†, Louise-Anne McNutt
5† and Anneli Uusküla
6†
Abstract
Background: Historically, HIV, TB (tuberculosis) and illegal drug treatment services in Estonia have been developed
as vertical structures. Related health care services are often provided by different health care institutions and in
different locations. This may present obstacles for vulnerable groups, such as injecting drug users (IDU), to access
the needed services. We conducted a small scale randomized controlled trial to evaluate a case management
intervention aimed at increasing TB screening and treatment entry among IDUs referred from a methadone drug
treatment program in Jõhvi, North-Eastern Estonia.
Findings: Of the 189 potential subjects, 112 (59%) participated. HIV prevalence was 86% (n = 96) and 7.4% (n = 8)
of participants were interferon gamma release assay (IGRA) positive (6.5% were both HIV and IGRA-positive, n = 7).
Overall, 44% of participants (n = 49) attended TB clinic, 17 (30%) from control group and 32 (57%) from case
management group (p = 0.004). None of the participants were diagnosed with TB. In a multivariate model, those
randomized to case management group were more likely to access TB screening services.
Conclusions: These findings demonstrate the urgent need for scaling up TB screening among IDUs and the value
of more active approach in referring substitution treatment patients to TB services.
Trial registration: ClinicalTrials.gov: NCT01290081
Background
Illegal drug use has become a risk factor for tuberculosis
(TB) as a result of the overlap of epidemiological and
social factors associated with both drug use and TB.
The spread of HIV infection has further amplified the
spread of TB among drug users [1,2]. An increase of
tuberculosis among relatively young individuals such as
injecting drug users (IDU) who often have active social
lives may have serious public health consequences and
lead to the spread of tuberculosis infection in the envir-
onment. Therefore, HIV infected persons and persons at
risk for HIV infection should be closely monitored for
TB even in a country where the prevalence of tuberculo-
sis is low [3].
Estonia, located in North-Eastern Europe, is the smal-
lest of the Baltic nations with a total population of
approximately 1.3 million people, had the TB incidence
rate of 26.2/100,000 in 2008; the proportion of multi-
drug resistant (MDR) cases (defined as TB caused by M.
tuberculosis resistant in vitro to isoniazid and rifampi-
cin) among new TB cases was 11.9% and among
relapses 29.5% respectively. The proportion of TB
patients co-infected with HIV was 9.4% [4,5]. Estonia
also has the highest numbers of newly diagnosed HIV
cases per 100,000 population in the European Union [6].
The adult injecting drug use prevalence (among 15-44
year old) is estimated to be 2.4% [7] and HIV-prevalence
r a t e sa sh i g ha s7 0 %h a v eb e e nd e s c r i b e da m o n gI D U s
[8]. Previous research has shown that up to 2% of IDUs
have been diagnosed with TB in lifetime. In neighboring
country Latvia this percentage is even higher - 7% [9].
Historically, HIV, TB and illegal drug treatment ser-
vices in Estonia have been developed as vertical struc-
tures. Related health care services are often provided by
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any medium, provided the original work is properly cited.different health care institutions and in different loca-
tions. This may present obstacles for vulnerable groups,
such as injecting drug users, to access the needed ser-
vices. Directly observed treatment short course (DOTS)
has been implemented in Estonia since 2000 and DOTS
plus strategy for MDR-TB treatment has been imple-
mented since August 2001. The DOTS and DOTS plus
coverage is 100%. Health care services related to TB
diagnostics and treatment are free of charge for all
patients [4].
International guidance often supports the idea of one-
stop shop or integration and co-location of HIV, tuber-
culosis and drug treatment services. While the fully inte-
grated approach should be viewed as the ideal situation,
it may not be attainable immediately due to funding
shortfalls or organizational and political constraints. As
such, it should be viewed as a goal to be evolved over
time [10]. In situations where co-locating services is not
possible, other measures can be implemented to
increase uptake and coverage of services. Most crucial is
efficient collaboration between different service provi-
ders. In programs that use additional outreach techni-
ques, such as assistance with transportation, incentives,
and food vouchers, very high levels of participation and
adherence have been achieved in populations facing the
most difficult barriers, such as homelessness, severe
mental illness, and active substance abuse [11-13].
The current project sought to test alternative methods
in referral of substitution treatment patients to TB con-
trol services in order to develop a model of collabora-
tion for TB and drug treatment services.
Methods
We conducted a small scale randomized controlled trial
to evaluate a case management intervention aimed at
increasing tuberculosis screening and treatment entry
among injecting drug users referred from a methadone
drug treatment program in Jõhvi, North-Eastern Estonia.
Setting and sample
Subjects were recruited from a community-based
methadone substitution treatment center in Jõhvi. The
center has 250 slots for treatment and operates seven
days a week. It is funded by the government and ser-
vices are free of charge for the patients.
Initial recruitment took place during regular business
hours of the treatment center in October 16-18, 2007.
All consecutive clients were approached for the study
participation.
Recruitment and study randomization was executed by
medical nurses who were full-time employers of the
substitutions treatment center. They received in-house
training regarding standardization of study protocol,
procedures to ensure confidentiality, and Mantoux
testing. They had been trained also on HIV counseling
and testing.
Eligibility criteria included participation in substitution
treatment program, age 18 years or more, able to read
and write in Estonian or Russian, and able to provide
informed consent. In order to link the data from differ-
ent study sites (substitution treatment center and TB
services) each participant was given a unique code.
Consenting participants were referred for TB screen-
ing (chest X-ray and additional tests if necessary) to the
tuberculosis department of the local county hospital
(distance between the two centers is approximately
16 km).
Study instruments and procedures
1. At the substitution treatment center:
1) Socio-demographic data, TB and IDU history,
imprisonment, and TB contacts were collected using
a semi-structured questionnaire which was modified
from multiple questionnaires [14-17]. The question-
naire was designed for self-administration and
required approximately 20 minutes to complete.
2) Whole venous blood was drawn for HIV and
interferon-g testing. Pre- and post-test counseling
was provided by study nurses. HIV test results were
available at the follow-up visit to Mantoux test read-
ing and interferon-g test results after three weeks of
initial participation.
3) HIV tests were performed at National HIV Refer-
ence Laboratory (using Vironostika HIV Uniform II
Ag/Ab; BioMerieux; positive cases were confirmed
with INNO LIA HIV I/II Score Westernblot).
4) Interferon-g testing was performed at National
Tuberculosis Reference Laboratory using an IGRA
assay (QuantiFERON-TB Gold; Cellestis Europe
©).
The technology is based on the measurement of
interferon-gamma (IFN-) secreted from stimulated
T-cells previously exposed to Mycobacterium tuber-
culosis [18]. CDC recommends interferon-gamma
release assays (IGRA) in place of TB skin testing in
all situations where tuberculin skin testing is recom-
mended as an aid in diagnosing M. tuberculosis
infection. An IGRA is preferred for testing persons
who have received BCG vaccination [19]. In Estonia,
BCG vaccination is part of the recommended immu-
nization schedule and is performed to all newborns
by the fifth day after birth [20].
5) Mantoux skin testing using 2TU of PPD 23 SSI.
Test results were read after 48-72 hours. Induration
of ≥5 mm was considered as positive result.
6) Participants who returned to skin test reading
were randomly assigned by the study nurses into
(1) passive referral group - control group (were
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vices themselves); or (2) active referral group - case
management intervention group (study personnel
scheduled the appointment and reminded to keep it,
transportation was organized when needed). Partici-
pants were expected to attend TB services within
the two months after the initial randomization. For
those who returned to skin test reading on time an
incentive was given (food voucher for local super-
market with the value of 6.4 EUR).
2. At the tuberculosis department:
1) Participants who attended TB services were
screened for active tuberculosis according to the
clinical guidelines of Estonian Respiratory Society
[21].
2) Medical doctors filled in a semi-structured ques-
tionnaire with the main demographic characteristics,
additional tests and procedures done, and the final
diagnosis of the participant based on ICD-10.
Statistical analysis
The interviewers filled questionnaires during the inter-
views, and checked them immediately after the inter-
view. Completed questionnaires were collected, checked
and reviewed for inaccuracies by supervisors on a daily
basis. All data was entered twice and the data sets were
compared to detect and correct any data entry errors.
Statistical analyses were performed with STATA 11.0
(StataCorp LP. College Station, TX). Descriptive statis-
tics were used to characterize participants by interven-
tion group and attendance to TB services. Associations
between participant characteristics and attendance to
TB services were evaluated by using the Wilcoxon rank-
sum test or Fisher exact test, followed by univariate and
multivariable logistic regressions.
Ethical committee
The study was approved by the Tallinn Medical
Research Ethics Committee and all participants provided
oral informed consent.
Results
Population characteristics
A total of 189 people were invited to participate in the
project. The study included 112 respondents (participation
rate 59%). The reasons for refusals were recent visit to TB
doctor (n = 34; 46%), no time to participate (n = 22; 29%),
did not want to fill in the questionnaire (n = 17; 25%).
Participants and refusals did not differ in mean age, and
gender. Timely return rate for skin test reading was 100%
and thus all people initially participating were randomized.
86% of participants (n = 96) were HIV-positive and
7.4% were IGRA-positive (n = 8). Among HIV-positive
participants 6.5% were IGRA-positive (n = 6) and
among HIV-negative participants - 14.3% (n = 2)(p =
0.3). Among IGRA-negative participants 13.0% (n = 14)
and among IGRA-positive - 62.5% were Mantoux-posi-
tive (n = 5)(p = 0.003).
None of the participants reported ever having had TB.
35 participants (31%) had had chest X-ray done in last
year before the study. 27 (24%) had the last X-ray more
than three years before the study and 12 (11%) did not
remember the time of the last X-ray.
Detailed socio-demographic characteristics, TB and
drug use history, and test results of the participants in
control and case-management groups are presented in
Table 1.
Attendance to TB services
By design, 56 (50%) were randomized to the interven-
tion and 56 (50%) to the control condition. There were
no baseline differences between the intervention and
control groups with respect to any socio-demographic
or behavioral characteristics, duration of injecting drug
use, previous exposure to TB or ever having had TB.
43.8% of participants (49/112) attended TB clinic,
17 (30.4%) from control group and 32 (57.1%) from case
management group (p = 0.004). None of them were
diagnosed with TB.
We examined the relationships between several poten-
tial predictive variables assessed at intake and the out-
come measure - attendance to TB services. Potential
predictors included age older than 29 years, female gen-
der, more than nine years of education, being employed,
injecting drugs less than 10 years, ever been in prison,
previous TB contacts, Mantoux and HIV test results,
and type of referral (active versus passive). Both in sim-
ple and multivariable logistic regression analysis none of
the candidate variables was significantly associated to
attendance to TB services, except for the type of referral.
Thus people from case management group had 3.9 (95%
CI 1.4-10.4) (p = 0.007) times higher odds of attending
TB services compared to those from control group.
Cost assessment
We conducted a cost assessment to quantify the expen-
ditures necessary to implement the active referral pro-
gram (detailed data are presented in Table 2). We did
not include the costs of tests performed at the substitu-
tion treatment center (these were performed solely for
the research purposes and do not have to be adminis-
tered routinely in this context) and costs related to TB
screening in TB clinic. We used the mean hourly salary
for medical nurses in Estonia. Thus for a substitution
treatment center to organize one client’s TB screening
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3,600 EUR.
Discussion
Drug users constitute a high-risk group for whom
screening, prevention of infection, diagnosis, and treat-
ment of TB may pose particular challenges. The devel-
opment of TB services capable of engaging drug users
(those both in and out of drug treatment programs) has
potential for disrupting a significant chain of rapid TB
transmission [1]. Drug treatment programs can provide
a strategic setting for screening and directly observed
preventive therapy, and for referring IDUs to needed
health care, especially for TB and antiretroviral therapies
[22,23].
None of our participants reported ever having had
tuberculosis. At the same time 6.5% of all participants
were positive for both HIV-antibodies and IGRA (as a
marker of latent TB). These people constitute an espe-
cially high risk group for developing active tuberculosis.
The risk of developing active TB could be as high as
5-10% per year [24].
Despite the fact that substitution treatment patients
attend the clinic daily and many of them who are
HIV-infected also attend infectious diseases clinics,
only one third of them had had a chest X-ray per-
formed within last 12 months prior to the recruitment.
These results show the need to implement more active
TB screening among methadone substitution treatment
patients.
Results of our pilot program show that the uptake of
TB screening services can be increased with more active
referral, help in transportation and incentives. Other
studies have also shown that monetary incentives can
increase participation in programs (for example the
return rate for TB skin test reading) [25].
Participants were very favorably inclined toward the
pilot program and the high acceptance rate of the initial
screening in substitution treatment center suggests that
this type of approach can be incorporated into daily
activities of substitution treatment program. Study staff
did not meet any major obstacles and problems related
to recruitment of participants, administration of the
questionnaire and referrals.
Table 1 Socio-demographic characteristics, TB and drug use history, and test results of the participants
Characteristic Total Control group Case management group
Male participants (%, 95% CI) 64.9 (55.8-73.9) 61.8 (48.7-74.9) 67.9 (55.4-80.3)
Mean age in years (SD; range) 26.2 (4.2; 19-48) 26.3 (3.1; 20-33) 26.0 (5.2; 19-48)
Sample younger than 30 years of age (%, 95% CI) 83.9 (77.0-90.8) 82.1 (71.9-92.4) 85.7 (76.4-95.1)
Ethnicity (%, 95% CI)
Estonian 9.8 (4.2-15.4) 8.9 (1.3-16.5) 10.7 (2.5-19.0)
Other 90.2 (84.6-96.8) 91.1 (83.5-98.7) 89.3 (81.0-97.5)
Persons with less than 12 years of education (%, 95% CI) 56.3 (46.9-65.6) 51.8 (38.4-65.1) 60.7 (47.7-73.8)
Percentage of employed participants (%, 95% CI) 49.1 (39.7-58.5) 48.2 (34.9-61.6) 50.0 (36.6-63.4)
Percentage of participants who had been in prison at least once in
lifetime (%, 95% CI)
61.6 (52.5-70.6) 67.9 (55.4-80.3) 55.4 (42.1-68.6)
Mean age at initiation of IDU (SD; range) 16.8 (3.3; 11-30) 17.3 (3.6; 11-26) 16.2 (3.0; 11-30)
Mean duration of IDU in years (SD; range) 9.4 (3.6; 2-24) 9.0 (3.4; 2-20) 9.8 (3.8; 4-24)
Percentage uninsured by the national health insurance (%, 95% CI) 36.6 (27.5-45.7) 35.7 (22.9-48.5) 37.5 (24.6-50.4)
Percentage of people with TB contacts (%, 95% CI) 24.1 (16.1-32.2) 66.7 (53.4-79.9) 81.1 (70.4-91.9)
Percentage of people who had had TB (%, 95% CI) 0.0 0.0 0.0
Percentage HIV-antibody positive 86.2 (79.7-92.8) 88.7 (80.0-97.4) 83.9 (74.1-93.7)
Percentage IGRA-positive (%, 95% CI) 7.4 (2.4-12.4) 9.4 (1.4-17.5) 5.5 (0.0-11.6)
Percentage Mantoux-positive (≥5 mm) (%, 95% CI) 17.0 (9.9-24.0) 19.6 (9.0-30.3) 14.3 (4.9-23.6)
Table 2 Costs related to referral of one patient
Task group Resources used Cost per unit Units per
patient
Price per
patient
Counseling and
referral
Nursing staff time 6.4 EUR per hour (including all taxes) 0.5 hour 3.2 EUR
Transportation Substitution treatment center’s
vehicle
2L of gas + 1 hour of driving staff time = 2 EUR +
6.4 EUR
1 8.4 EUR
Incentives Food voucher 6.4 EUR per voucher 1 voucher 6.4 EUR
Total 18 EUR
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additional investments the uptake of TB screening for
IDUs can be considerably increased. In comparision -
the mean cost of non-MDR-TB treatment case in Esto-
nia is 3,251 EUR and of the MDR-TB patient - 8,469
EUR [26]. Early detection of TB improves the treatment
outcomes [27] and reduces the period of infectiousness
thus investment in TB screening for IDUs can be cost
saving.
Limitations
Small sample size, recruitment in only one centre, and
sampling in methadone treatment program would not
have accessed important groups of active injecting drug
users, and therefore the results cannot be generalized to
the whole IDU population. Generalisability might be
further affected by the modest response rate among
methadone center clients. Further, given that the HIV
prevalence among methadone center clients was very
high additional research is needed in terms on need and
methods for screening among IDUs not in contact with
harm reduction services. However, the main reason for
declining study participation was recent contact with TB
services and thus our intervention reached those in
most need for TB screening.
Conclusions
This pilot study illustrates the urgent need for scaling
up TB screening among IDUs and the value of more
active approach in referring substitution treatment
patients to TB services.
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